Our aim was to demonstrate that G. elata-specific miRNA can regulate GSK-3β, leading to the inhibition of Tau protein hyperphosphorylation and ultimately providing neuroprotection against AD. The gene discussed is MAPT; the disease is Alzheimer disease.